Key facts
- MI:RNA’s last known valuation is $9.6M (Jul 2024).
- It has raised $9.2M across 2 recorded rounds; the latest was Seed Round ($4.4M) in Jun 2024.
- Notable investors include Scottish Enterprise, NovaQuest Capital Management, Ani.VC, Animal Health Angels, Barwell — 16 tracked in total.
- MI:RNA has filed 2 Form Ds with the SEC since 2023, most recently Nov 2024 ($4.4M sold to 57 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for MI:RNA
Funding rounds
2 roundsAbout MI:RNA
Operator of a veterinary diagnostics company intended to develop and market testing technology for early-stage heart disease in companion animals. The company specializes in the development of testing technology for veterinary diseases and offers companion animal tests using serum biomarkers and AI modeling, enabling pets to improve treatment outcomes and quality of life for pets.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2019
- Employees
- 36
- Website
- mirna.tech/
- Ownership
- Privately Held (backing)
MI:RNA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MI:RNA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MI:RNA in its N-PORT filings yet. We sweep new filings monthly.